The program has been transitioned to a permanent pathway that is designed to support innovative tools like artificial intelligence, wearables, and biomarkers in drug development and trials.

Chemma’s development comes amid criticism of LLMs, such as GPT-4, that have ‘hallucinated’ or generated incorrect results, ...

Digital twin system offers a way to test hypotheses and therapeutics before live cell experimentsA researcher team drawn from ...

Co-authors: Roger Hancock, CEO of Recall InfoLink, and Gillian Kelleher, president and CEO of Kelleher Consultants LLC. -- OPINION -- On July 9, the FDA ...

The global biosimulation market is set for explosive growth, with a new forecast predicting its valuation will increase from ...

Company closes approximately $5.47 million in equity financing in 2Q/3Q25-TH104 potentially fills a critical National Security Need against Weaponized Fentanyl–TH023 may fulfill the promise of ...

No longer confined to the realms of gaming or cryptocurrency, technologies like Virtual Reality (VR), Augmented Reality (AR), ...

In a laboratory more than 249 miles above Earth, a new generation of cancer research is unfolding. A biotech startup is harnessing the microgravity environment of ...